$TEM

LEFKOFSKY ERIC P sold $1.1M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 24,318 indirectly-held shares of Tempus AI, Inc. (TEM) at $46.89 ($1.14M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published May 29, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

Open-market insider sales can pressure sentiment, but 10b5-1 pre-arranged plans typically limit the inference traders draw about near-term fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to be a standalone catalyst.

03

What to watch

The filing does not provide context on total insider selling cadence, whether other insiders sold/bought, or whether the sale size is large relative to holdings beyond the post-transaction balance.

Relevance 7/10Novelty 4/10Timing: SEC Form 4 filed May 29 covering sales executed May 27

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO/Chairman and 10% owner LEFKOFSKY Eric P sold $1.14M of TEM shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Low probability of a sustained price move; any reaction is likely short-lived unless accompanied by other catalysts.

Evidence & confidence

The filing is a routine insider transaction and explicitly states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider sale; CEO/Chairman and 10% owner sold shares under a 10b5-1 plan.

  • LEFKOFSKY ERIC P

    CEO and Chairman; executed an open-market sale of 24,318 shares at $46.8900.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.